Clinical Trial Update: PREPARE (A5361s) Ancillary Study of REPRIEVE (A5332) [Phase 3]

View source ↗

Summary

Phase 3 ancillary study PREPARE (A5361s) of REPRIEVE (A5332) has completed and results were posted on 2024-10-28.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Snippet

Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Conditions: HIV-1 Infection | Phase 3 | Status: COMPLETED | Results posted: 2024-10-28